GGrantIndex
← Search

CONCURRENT RADIATION AND GEMCITABINE FOR UNRESECTABLE HEAD AND NECK TUMORS

$0M01FY2000RRNIH

University Of Michigan At Ann Arbor, Ann Arbor MI

Investigators

Linked publications & trials

Abstract

This is a phase I study seeking the maximally tolerated dose of gemcitabine delivered concurrent with a standard course of radiation for patients with unresectable head and neck tumors. Plasma levels and tumor incorporation of gemcitabine, as well as tumor nucleotide pools will be measured in order to gain a better understanding of the mechanisms by which gemcitabine may enhance radiation antitumoral activity in vivo.

View original record on NIH RePORTER →